Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1382 participants.

Also called NCT06316570

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,382 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06316570
Other papers using this trial's data
  • Ticagrelor with aspirin dual antiplatelet therapy combined with intravenous thrombolysis in patients with ischaemic stroke in China (TAPIS): a multicentre, double-blind, randomised controlled trial Lancet (London, England), 2026-05-16 DOI, PubMed 42114550
  • Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis Stroke, 2026-10 DOI, PubMed 42689322

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06316570. Randomized; triple masking; primary purpose treatment. Start 2024-04-03 (actual); primary completion 2025-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke
Acronym
TAPIS
Condition
Ischemic Stroke, Acute
Intervention (Drug)
Early Dual Antiplatelet Therapy
Intervention (Drug)
Placebo
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct06316570
Content hash
c8cb84b57e198ed5f5d4852bfc5d21611ec9d3fb4800a962b60c4278554e7f8b